Forrest General Performs State’s First Minimally-Invasive Procedure for Severe Mitral Regurgitation with the New and Improved G4 MitraClip™ Device
HATTIESBURG, Miss. – (August 19, 2020) The cardiology team at Forrest General Hospital has successfully performed mitral valve repair using the newly-innovative G4 MitraClip device™. This procedure is a minimally invasive treatment option for people with a severe leak in the mitral valve who are too high-risk for traditional open-heart surgery or select heart patients who remain symptomatic despite guideline-directed medical therapy (GDMT). The condition, called mitral regurgitation (MR), is one of the most common heart valve diseases.
With this procedure, Forrest General becomes the first in the state to use the new MitraClip™ G4 technology. In January of 2017, Forrest General became the first hospital in Mississippi to treat mitral regurgitation using transcatheter mitral valve repair (TMVR) with MitraClip™ therapy.
“The MitraClip procedure is very important to our high-risk patients who have no other option for improving their health,” said Christopher Douglas, M.D., Hattiesburg Clinic Heart & Vascular. “We are excited to be the first in the state to offer this cutting edge new generation technology to our patients for optimal results.”
A leak in the mitral valve occurs when the leaflets, or flaps, of the mitral valve do not close completely, allowing blood to flow back into the heart as it pumps. The heart has to work harder, as a result, to keep blood flowing and can raise the risk for life-threatening stroke and heart failure. When MR becomes severe, it can profoundly affect a person’s quality-of-life by causing shortness of breath, extreme fatigue, and other debilitating symptoms. If left untreated, MR can ultimately lead to heart failure and death.
For MR patients who are ineligible for surgery or select heart failure patients who remain symptomatic despite GDMT, the most advanced MitraClip system, MitraClip G4, offers a safe and effective treatment option that can improve quality of life.
The MitraClip device is delivered to the heart through a small incision in the leg and clips portions of the leaflets of the mitral valve together to reduce the backflow of blood, restoring the heart’s ability to pump oxygenated blood more efficiently. Patients tend to have a short hospital stay – on average, two days – and experience improved heart function and symptoms almost immediately. MitraClip is now on a fourth generation of innovations and offers new advancements and additional options for doctors treating mitral valve disease. The therapy has now treated more than 100,000 patients worldwide.
“We believe the new G4 MitraClip device is going to allow us to treat a broader spectrum of the patient population with severe mitral regurgitation,” said Douglas. “We look forward to this technology providing our patients solutions to their healthcare needs.”
About Forrest General’s Cardiac Services
Forrest General’s Heart and Vascular Services delivers expert care from board-certified cardiologists, cardiovascular surgeons and vascular surgeons. Services range from diagnostic testing, heart surgery and structural heart treatment to Interventional cardiology, Cardiac rehabilitation and Vascular treatment. To learn more about services, advanced treatment options or heart disease risks, signs and symptoms, visit www.forrestgeneral.com/heart.
MitraClip is a small, clip-based device has proven to repair primary and secondary MR without the need for open-heart surgery. The device is delivered to the heart through a small incision in the leg and works by clipping together a portion of the leaflets of the mitral valve to reduce the backflow of blood, which allows the heart to pump blood more efficiently.
The MitraClip system has been commercially available in the U.S. since 2013 and in Europe since 2008. With more than 16 years of clinical experience and more than 100,000 patients treated worldwide, the MitraClip system is the first transcatheter mitral valve therapy with proven safety and the only with proven survival and durable clinical outcomes.
CAPTION: Taking part in the MitraClip-G4 repair procedure were, from left, Philip Mangrum, and Jonathan Ojeda, Abbott representatives; Pat Peterson, Radiology tech; Dr. Chris Douglas; Kristin Sullivan, Radiology tech; Dr. Craig Thieling; and Dr. Adam Harless.